The Life Sciences team advised Karuna Therapeutics, Inc. (Nasdaq: KRTX) through its completion of underwritten public offering of 2,600,000 shares of its common stock at a price to the public of $96.00 per share for aggregate gross proceeds of approximately $250.0 million. In addition, Karuna has granted the underwriters a 30-day option to purchase an additional 390,000 shares of its common stock, at the public offering price, less the underwriting discounts and commissions.
Karuna Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain.
The Goodwin team was led by Mitchell Bloom, Seo Salimi, Nicole Daley and Isabel Klosterman (Corporate), and included Stephanie Philbin and Elizabeth Mulkey (FDA Regulatory), Janet Andolina and Matthew Dunay (Tax), Roger Cohen and Bryna Shmerling (Healthcare), Olivia Uitto (IP), and Caroline Bullerjahn (Securities Litigation), with invaluable assistance from Pamela Finan.
For more information, read the press release.